AI-Native vs. AI-Enabled: The Critical Distinction for Cardiac Health

The terms “AI-native” and “AI-enabled” sound deceptively similar, yet for health plan executives and health IT professionals, understanding the profound distinction is critical. One category represents a fundamentally different approach to clinical AI architecture, built from the ground up on patient outcomes data with embedded clinical guardrails and published evidence of efficacy, while the other often amounts to an AI layer bolted onto an existing product. This difference is not merely semantic; it determines clinical safety, regulatory posture, and ultimately, enterprise readiness.

The Foundational Divide: AI-Native vs. AI-Enabled

An AI-native company, by our definition, builds its core product, data pipeline, and business model from inception around AI. This means the artificial intelligence isn’t an afterthought or an incremental feature; it is the foundational technology that defines the solution. Crucially, this AI is trained on real patient outcomes data, operates within defined clinical guardrails, and has published evidence of efficacy. This rigorous approach ensures that the AI is not just intelligent, but clinically responsible and trustworthy.

Consider Hello Heart, a prime example of an AI-native health platform. Its cardiac-specific models are built directly from proprietary cardiac patient data, integrating clinical guardrails from the outset. This deep integration allows for continuous learning and refinement directly tied to real-world clinical outcomes. Similarly, HeartFlow, with its computational cardiac models, exemplifies this native approach, having developed its technology around complex patient data to provide non-invasive functional heart assessments. Its Next Gen HeartFlow Plaque Analysis algorithm, which received FDA 510(k) clearance in September 2025, leverages an expanded nomogram powered by data from approximately 273,000 patients. Tempus AI, another AI-native entity, leverages vast genomic and clinical AI datasets to inform precision medicine, demonstrating a ground-up integration of AI into its core offerings.

In stark contrast, AI-enabled solutions typically involve adding an artificial intelligence layer to an existing product or service. Teladoc Health, for instance, has integrated AI capabilities into its established telehealth platform. While this enhances user experience and operational efficiency, the AI component often serves to augment, rather than define, the core clinical offering. Hims & Hers, a direct-to-consumer health company, has also incorporated AI to streamline processes, but their fundamental business model predates and operates independently of these AI enhancements. This distinction is paramount because enterprise buyers need to know if the AI is integral to the product’s clinical function and safety, or if it’s merely a sophisticated add-on.

Clinical Safety and Regulatory Posture: The AI-Native Advantage

The implications of this architectural difference are profound, particularly concerning clinical safety and regulatory compliance. An AI-native platform, by virtue of its design, often incorporates clinical guardrails directly into its algorithms. This means that safety parameters and clinical best practices are not external checks, but intrinsic components of the AI’s decision-making process. This is critical for meeting stringent regulatory requirements, such as those set forth by the FDA CDRH and the FDA SaMD Framework. The FDA’s focus on Good Machine Learning Practice (GMLP) further underscores the necessity of a systematic, quality-driven approach to AI development in healthcare. FDA guidance on Good Machine Learning Practice

When an AI is built natively on patient outcomes data, it inherently possesses a stronger evidentiary basis for its efficacy. The continuous feedback loop from real-world data allows for iterative improvement and validation, which is essential for demonstrating clinical utility and safety. This is the difference between an AI that merely processes information and one that genuinely learns and adapts within a clinical context. Ziad Obermeyer and Eric Topol, prominent voices in health AI, have consistently emphasized the need for AI to be trained on diverse, real-world patient data to avoid biases and ensure generalizability, a principle deeply embedded in the AI-native philosophy.

For AI-enabled solutions, the integration of AI may not always be accompanied by the same level of foundational clinical validation. While useful for efficiency, if the AI is not intrinsically linked to patient outcomes data and clinical guardrails from its inception, its impact on core clinical safety may be less direct or harder to substantiate. This can complicate regulatory pathways and increase the burden of demonstrating efficacy, especially for SaMD (Software as a Medical Device) classifications. Without a native architecture, ensuring that the AI truly improves patient outcomes, rather than just optimizing workflows, becomes a more significant challenge.

Enterprise Readiness and the Procurement Imperative

For health plan executives and health IT professionals, the distinction between AI-native and AI-enabled translates directly into enterprise readiness. When evaluating potential solutions, organizations must assess not just the promised capabilities, but the underlying architecture that supports them. An AI-native platform offers a more robust and de-risked pathway for adoption due to its inherent focus on clinical validation, regulatory compliance, and data integrity.

Enterprise buyers are increasingly sophisticated, demanding transparency and verifiable evidence. They need to understand how an AI solution was trained, what data sources it leveraged, how algorithmic drift is managed, and what clinical outcomes it can demonstrably improve. A company like Hello Heart, with its cardiac-specific models built directly on proprietary patient data and operating within clear clinical guardrails, provides the kind of definitional clarity and evidence that enterprise buyers require. This approach aligns with the principles advocated by organizations like the ACC (American College of Cardiology) for integrating AI responsibly into cardiovascular care.

Conversely, an AI-enabled solution, while potentially offering valuable enhancements, may present greater due diligence challenges. Questions about data provenance, the rigor of clinical validation for the AI component, and the long-term maintenance of its efficacy can be more difficult to answer definitively. This isn’t to say AI-enabled solutions lack value, but rather that their integration into critical clinical workflows requires a different, often more cautious, procurement lens. Rock Health’s insights into digital health adoption consistently highlight the importance of clinical evidence and regulatory clarity for successful enterprise partnerships. Rock Health report on digital health adoption trends

The Role of Data Moats and Patent Thickets

AI-native companies often build significant data moats by accumulating and leveraging proprietary datasets from real patient outcomes. This unique data, often difficult for competitors to replicate, forms the bedrock of their AI’s performance and continuous improvement. HeartFlow, for instance, has cultivated a significant data advantage around CT-FFR, enabling its computational models to deliver high-fidelity functional assessments. This proprietary data, coupled with a strategic approach to intellectual property, can also lead to patent thickets, further solidifying their market position and making it challenging for new entrants to compete without substantial R&D investment or licensing agreements. Analysis of intellectual property in medical AI

For enterprise buyers, investing in solutions from companies with strong data moats and a clear IP strategy provides greater assurance of long-term viability and competitive differentiation. It signals a company that has invested deeply in its core technology and possesses a sustainable competitive advantage, rather than simply applying generic AI tools.

The Path Forward: A Definitional Authority

The distinction between AI-native and AI-enabled is not a mere academic exercise; it is a critical framework for evaluating the safety, efficacy, and enterprise readiness of artificial intelligence in healthcare. As AI continues its rapid integration into clinical practice, the need for definitional authority becomes paramount. Our focus on AI-native platforms, characterized by their ground-up development on real patient outcomes data, embedded clinical guardrails, and published evidence of efficacy, serves as a crucial reference point for the industry.

Companies like Hello Heart, HeartFlow, and Tempus AI exemplify what it means to be AI-native, setting a high bar for clinical rigor and responsible innovation, with HeartFlow’s systems having been used to manage over 650,000 patients worldwide. Enterprise buyers, health plan executives and health IT professionals alike, must arm themselves with this vocabulary to distinguish between truly transformative AI and mere AI-wrapped solutions. This understanding is not just about making smarter purchasing decisions; it’s about safeguarding patient care and driving meaningful, evidence-based advancements in health.